SCHEMBL2897387

SCHEMBL2897387

Cc1ccc(C(=O)N2CCC(OC(=O)C(F)(F)F)(c3ccccc3)CC2)c(NCc2ccco2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
REN P00797 2/20 0.63
ALDH1A1 P00352 9/20 0.38
MAPT P10636 6/20 0.38
KMT2A Q03164 4/20 0.38
NPSR1 Q6W5P4 4/20 0.38
MEN1 O00255 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38
HRH4 Q9H3N8 2/20 0.37
MAPK1 P28482 1/20 0.36
LMNA P02545 6/20 0.36
TSHR P16473 3/20 0.36
KDM4E B2RXH2 6/20 0.35
SMN1; SMN2 Q16637 4/20 0.35
HPGD P15428 2/20 0.35
HSD17B10 Q99714 2/20 0.35
GAA P10253 2/20 0.35
GLA P06280 1/20 0.35
THRB P10828 1/20 0.35
F2 P00734 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2897383 0.87 REN (0.67) RENALDH1A1MAPTKMT2ANPSR1
SCHEMBL13295305 0.84 REN (0.72) RENALDH1A1MAPTKMT2ANPSR1
SCHEMBL2897168 0.78 REN (1.00) RENALDH1A1MAPTKMT2ANPSR1
SCHEMBL2894274 0.75 REN (0.47) RENALDH1A1SMN1; SMN2
SCHEMBL2902712 0.71 REN (0.68) RENALDH1A1MAPTKMT2ANPSR1
Trifluoroacetic Acid SCHEMBL2939655 0.71 REN (0.70) RENALDH1A1KMT2AMEN1HRH4
SCHEMBL12990642 0.71 REN (0.65) RENALDH1A1MAPTKMT2ANPSR1
SCHEMBL2912713 0.69 REN (0.67) RENALDH1A1MAPTKMT2ANPSR1
Trifluoroacetic Acid SCHEMBL2894272 0.69 REN (0.49) RENALDH1A1KDM4ESMN1; SMN2
SCHEMBL12991017 0.67 REN (0.77) RENALDH1A1KMT2AMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2202228-B1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL (JP) 2014-12-10 EP disclosed
US-8329691-B2 Amide compounds and use of the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-12-11 US disclosed
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-23 US disclosed
EP-2202228-A1 AMIDE COMPOUNDS AND USE OF THE SAME Takeda Pharmaceutical Company Limited (JP) 2010-06-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324010-A1 AMIDE COMPOUNDS AND USE OF THE SAME REN, ACE, AGT REN 1/4885ALDH1A1 897/4885MAPT 3228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.